Novartis (NVS) Stock Forecast, Price Target & Predictions
NVS Stock Forecast
Novartis stock forecast is as follows: an average price target of $116.33 (represents a 12.02% upside from NVS’s last price of $103.85) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.
NVS Price Target
NVS Analyst Ratings
Hold
Novartis Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 30, 2024 | Etzer Darout | BMO Capital | - | - | 9.18% | 15.55% |
Sep 05, 2024 | James Quigley | Goldman Sachs | - | - | 1.36% | 16.51% |
Jul 19, 2024 | Etzer Darout | BMO Capital | - | - | 11.18% | 13.63% |
Apr 23, 2024 | Wan Nurhayati | CFRA | - | - | 11.03% | 4.00% |
10
Novartis Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 2 | 4 |
Avg Price Target | $120.00 | $120.50 | $116.75 |
Last Closing Price | $103.85 | $103.85 | $103.85 |
Upside/Downside | 15.55% | 16.03% | 12.42% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 30, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
Sep 05, 2024 | Goldman Sachs | Buy | Neutral | Downgrade |
Sep 02, 2024 | Jefferies | Buy | Hold | Downgrade |
Jul 19, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
Jul 19, 2024 | Deutsche Bank | Hold | Downgrade | |
Jul 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Jul 11, 2024 | Oddo BHF | Outperform | Upgrade | |
Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
May 30, 2024 | Goldman Sachs | Buy | Initialise | |
Apr 24, 2024 | UBS | Buy | Buy | Hold |
10
Novartis Financial Forecast
Novartis Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | $13.21B | $13.09B | $12.84B | $13.09B | $12.81B | $13.52B | $13.37B | $13.29B | $12.69B | $13.03B | $12.54B | $11.62B | $12.71B | $12.72B | $12.48B | $12.02B | $11.46B | $12.93B | $11.79B |
Avg Forecast | $12.25B | $12.85B | $13.09B | $12.66B | $12.97B | $12.79B | $12.45B | $11.44B | $11.88B | $12.42B | $13.47B | $12.72B | $13.22B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $12.93B | $11.57B |
High Forecast | $12.40B | $13.01B | $13.25B | $12.82B | $13.37B | $12.86B | $12.49B | $11.44B | $12.25B | $12.65B | $13.64B | $12.88B | $13.39B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $15.51B | $13.89B |
Low Forecast | $12.12B | $12.71B | $12.95B | $12.65B | $12.67B | $12.72B | $12.41B | $11.44B | $11.59B | $12.28B | $13.33B | $12.58B | $13.08B | $12.88B | $12.88B | $12.62B | $13.33B | $13.06B | $12.55B | $12.50B | $12.90B | $12.60B | $11.84B | $12.00B | $12.33B | $11.70B | $11.49B | $11.09B | $10.34B | $9.26B |
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.99% | 1.00% | 1.02% | 1.02% | 1.01% | 1.02% | 1.06% | 1.02% | 1.01% | 0.99% | 0.98% | 1.06% | 1.03% | 1.07% | 1.05% | 1.03% | 1.00% | 1.02% |
Forecast
Novartis EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | $4.95B | $3.91B | $4.16B | $4.05B | $4.28B | $18.68B | $4.88B | $5.15B | $4.35B | $4.37B | $4.36B | $4.21B | $4.27B | $3.90B | $4.03B | $8.57B | $3.71B | $2.63B | $3.90B |
Avg Forecast | $3.95B | $4.15B | $4.22B | $4.09B | $4.19B | $4.13B | $4.02B | $5.18B | $3.84B | $4.01B | $4.35B | $4.71B | $4.27B | $5.16B | $5.16B | $4.28B | $5.34B | $5.23B | $5.03B | $4.54B | $5.17B | $5.05B | $4.74B | $3.68B | $4.94B | $4.69B | $4.60B | $3.55B | $2.63B | $3.83B |
High Forecast | $4.00B | $4.20B | $4.28B | $4.14B | $4.31B | $4.15B | $4.03B | $6.21B | $3.95B | $4.08B | $4.40B | $5.65B | $4.32B | $5.16B | $5.16B | $5.13B | $5.34B | $5.23B | $5.03B | $5.45B | $5.17B | $5.05B | $4.74B | $4.42B | $4.94B | $4.69B | $4.60B | $4.25B | $3.16B | $4.60B |
Low Forecast | $3.91B | $4.10B | $4.18B | $4.08B | $4.09B | $4.11B | $4.01B | $4.14B | $3.74B | $3.96B | $4.30B | $3.76B | $4.22B | $5.16B | $5.16B | $3.42B | $5.34B | $5.23B | $5.03B | $3.63B | $5.17B | $5.05B | $4.74B | $2.94B | $4.94B | $4.69B | $4.60B | $2.84B | $2.10B | $3.07B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 0.92% | 0.81% | 0.78% | 1.00% | 3.50% | 0.93% | 1.02% | 0.96% | 0.85% | 0.86% | 0.89% | 1.16% | 0.79% | 0.86% | 1.86% | 1.05% | 1.00% | 1.02% |
Forecast
Novartis Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | $2.29B | $1.47B | $1.57B | $1.69B | $2.22B | $16.31B | $2.76B | $2.90B | $2.06B | $2.09B | $1.94B | $1.87B | $2.18B | $1.13B | $2.04B | $6.80B | $1.77B | $2.02B | $1.67B |
Avg Forecast | $4.08B | $4.29B | $4.46B | $4.00B | $3.77B | $3.93B | $3.75B | $2.69B | $3.35B | $3.38B | $3.32B | $2.44B | $18.44B | $3.01B | $2.92B | $2.22B | $2.75B | $3.17B | $3.02B | $2.15B | $2.65B | $2.80B | $2.57B | $1.87B | $2.55B | $2.57B | $2.35B | $1.69B | $2.02B | $1.64B |
High Forecast | $4.15B | $4.36B | $4.53B | $4.07B | $3.97B | $3.95B | $3.75B | $3.23B | $3.61B | $3.43B | $3.38B | $2.93B | $22.12B | $3.01B | $2.92B | $2.67B | $2.75B | $3.17B | $3.02B | $2.58B | $2.65B | $2.80B | $2.57B | $2.25B | $2.55B | $2.57B | $2.35B | $2.03B | $2.43B | $1.96B |
Low Forecast | $4.03B | $4.23B | $4.40B | $3.95B | $3.58B | $3.91B | $3.75B | $2.15B | $3.13B | $3.36B | $3.28B | $1.96B | $14.75B | $3.01B | $2.92B | $1.78B | $2.75B | $3.17B | $3.02B | $1.72B | $2.65B | $2.80B | $2.57B | $1.50B | $2.55B | $2.57B | $2.35B | $1.35B | $1.62B | $1.31B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.08% | 0.52% | 0.58% | 1.00% | 5.93% | 0.87% | 0.96% | 0.96% | 0.79% | 0.69% | 0.73% | 1.16% | 0.44% | 0.79% | 2.90% | 1.05% | 1.00% | 1.02% |
Forecast
Novartis SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | $3.44B | $3.75B | $3.41B | $3.58B | $3.51B | $3.98B | $3.62B | $3.75B | $3.53B | $3.92B | $3.42B | $3.37B | $3.49B | $3.90B | $3.55B | $3.58B | $3.33B | $3.92B | $3.47B |
Avg Forecast | $3.44B | $3.61B | $3.68B | $3.55B | $3.64B | $3.59B | $3.50B | $4.25B | $3.34B | $3.49B | $3.78B | $3.86B | $4.51B | $3.62B | $3.62B | $3.51B | $3.74B | $3.67B | $3.53B | $3.68B | $3.62B | $3.54B | $3.33B | $3.00B | $3.46B | $3.29B | $3.23B | $3.19B | $3.92B | $3.41B |
High Forecast | $3.48B | $3.65B | $3.72B | $3.60B | $3.75B | $3.61B | $3.51B | $5.10B | $3.44B | $3.55B | $3.83B | $4.64B | $5.41B | $3.62B | $3.62B | $4.21B | $3.74B | $3.67B | $3.53B | $4.42B | $3.62B | $3.54B | $3.33B | $3.60B | $3.46B | $3.29B | $3.23B | $3.82B | $4.71B | $4.09B |
Low Forecast | $3.40B | $3.57B | $3.64B | $3.55B | $3.56B | $3.57B | $3.48B | $3.40B | $3.25B | $3.45B | $3.74B | $3.09B | $3.60B | $3.62B | $3.62B | $2.81B | $3.74B | $3.67B | $3.53B | $2.95B | $3.62B | $3.54B | $3.33B | $2.40B | $3.46B | $3.29B | $3.23B | $2.55B | $3.14B | $2.73B |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 0.83% | 0.94% | 0.99% | 1.00% | 1.06% | 0.99% | 1.06% | 0.96% | 1.08% | 0.97% | 1.01% | 1.16% | 1.13% | 1.08% | 1.11% | 1.05% | 1.00% | 1.02% |
Forecast
Novartis EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 17 |
EPS | - | - | - | - | - | - | - | - | - | - | - | $1.09 | $0.69 | $0.73 | $0.77 | $1.00 | $7.29 | $1.23 | $1.29 | $0.91 | $0.92 | $0.85 | $0.82 | $0.96 | $0.50 | $0.90 | $2.94 | $0.77 | $0.87 | $0.70 |
Avg Forecast | $2.02 | $2.12 | $2.20 | $1.98 | $1.86 | $1.94 | $1.85 | $1.68 | $1.65 | $1.67 | $1.64 | $1.45 | $1.35 | $1.47 | $1.43 | $1.38 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.28 | $1.09 |
High Forecast | $2.05 | $2.15 | $2.24 | $2.01 | $1.96 | $1.95 | $1.85 | $1.73 | $1.78 | $1.69 | $1.67 | $1.46 | $1.37 | $1.47 | $1.43 | $1.40 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.54 | $1.31 |
Low Forecast | $1.99 | $2.09 | $2.17 | $1.95 | $1.77 | $1.93 | $1.85 | $1.63 | $1.54 | $1.66 | $1.62 | $1.44 | $1.33 | $1.47 | $1.43 | $1.35 | $1.34 | $1.55 | $1.47 | $1.46 | $1.30 | $1.37 | $1.26 | $1.32 | $1.25 | $1.26 | $1.15 | $1.05 | $1.02 | $0.87 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.51% | 0.50% | 0.54% | 0.73% | 5.42% | 0.79% | 0.88% | 0.62% | 0.71% | 0.62% | 0.65% | 0.73% | 0.40% | 0.72% | 2.56% | 0.73% | 0.68% | 0.64% |
Forecast
Novartis Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PFE | Pfizer | - | - | 78.11% | Hold |
GSK | GSK | - | - | 72.11% | Hold |
AZN | AstraZeneca | - | - | 30.72% | Buy |
MRK | Merck | - | - | 29.07% | Buy |
SNY | Sanofi | - | - | 19.55% | Buy |
JNJ | Johnson & Johnson | - | - | 15.20% | Buy |
BMY | Bristol-Myers Squibb Company | - | - | 12.48% | Hold |
NVS | Novartis | - | - | 12.02% | Hold |
LLY | Eli Lilly and Company | - | - | 3.76% | Buy |
ABBV | AbbVie | - | - | 0.91% | Buy |
GILD | Gilead Sciences | - | - | -8.90% | Buy |